ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Antibody > Nucleocapsid protein > NUN-CH15

Anti-SARS-CoV-2 Nucleocapsid Antibody, Chimeric mAb, Human IgG1 (AM223) (MALS verified)

  • Source
    Anti-SARS-CoV-2 Nucleocapsid Antibody, Chimeric mAb, Human IgG1 is a chimeric monoclonal antibody recombinantly expressed from CHO cells, which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain. The mouse monoclonal antibody was obtained from a mouse immunized with recombinant SARS-CoV-2 Nucleocapsid Protein. This chimeric antibody is purified by Protein A affinity chromatography. As verified by binding test with N-NTD (Cat. No. NUN-C5143) and N-CTD (Cat. No. NUN-C5145) protein, this antibody can only bind to N-CTD (AA Ser 255 - Pro 364). It can also bind multiple N protein variants with similar affinity as compared to the wild type N protein (Cat. No. NUN-C5227).
  • Clone

    AM223

  • Isotype

    Human IgG1 | Human Kappa

  • Conjugate

    Unconjugated

  • Antibody Type

    Recombinant Monoclonal

  • Reactivity

    Virus

  • Specificity

    This product can recognize SARS-CoV-2 Nucleocapsid protein. Cross-reactivity with Nucleocapsid protein of other coronaviruses has not been tested.

  • Application
    ApplicationRecommended Usage
    ELISA0.2-50 ng/mL
  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Purification

    Protein A purified/ Protein G purified

  • Formulation

    Supplied as 0.2 μm filtered solution in PBS, pH7.4.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. For long term storage, the product is stable for up to 3 years at -70°C from date of receipt;
    2. For short term storage, the product is stable for up to 12 months at 2-8°C from date of receipt.
SDS-PAGE
Nucleocapsid protein SDS-PAGE

Anti-SARS-CoV-2 Nucleocapsid Antibody, Chimeric mAb, Human IgG1 (AM223) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS
Nucleocapsid protein MALS images

The purity of Anti-SARS-CoV-2 Nucleocapsid Antibody, Chimeric mAb, Human IgG1 (AM223) (Cat. No. NUN-CH15) is more than 95% and the molecular weight of this protein is around 130-160 kDa verified by SEC-MALS.

Bioactivity-ELISA
 Nucleocapsid protein ELISA

Immobilized SARS-CoV-2 (COVID-19) Nucleocapsid protein, His Tag (Cat. No. NUN-C5227) at 2μg/mL (100μL/well) can bind Anti-SARS-CoV-2 Nucleocapsid Antibody, Human IgG1 (AM223) (Cat. No. NUN-CH15) with a linear range of 0.2-6 ng/mL (Routinely tested).

 Nucleocapsid protein ELISA

Immobilized Anti-SARS-CoV-2 Nucleocapsid Antibody, Human IgG1 (AM223) (Cat. No. NUN-CH15) at 1μg/mL (100μL/well) can bind SARS-CoV-2 Nucleocapsid protein, His Tag (B.1.1.529/Omicron) (Cat. No. NUN-C52Ht) with a linear range of 0.2-6 ng/mL (Routinely tested).

  • Background
    Nucleocapsid (N) protein is the most abundant protein found in coronavirus. CoV N protein is a highly immunogenic phosphoprotein important for viral genome replication and modulation of cell signaling pathways. It was first identified by a research team while they were screening for ADP-ribosylated proteins during coronavirus (CoV) infection (Grunewald M. E., et al. 2017, Virology; 517: 62-68). The array of diverse functional activities accommodated in N protein makes it more than a structural protein but also an interesting target in the development of antiviral therapeutics. Because of the conservation of N protein sequence and its strong immunogenicity, N protein of coronavirus is chosen as a diagnostic tool.
  • Clinical and Translational Updates

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : Inquire

価格(JPY) : 212,800

価格(JPY) : 700,000

価格(JPY) : 5,600,000

価格(JPY) : 44,800,000

プロモーション&展示



医薬品開発状況

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:1 Details
  • Latest Research Phase:Phase 1 Clinical

データシート&ドキュメンテーション

DMF請求
DMF (Drug Master File)

新製品

お問い合わせ&コメント

This web search service is supported by Google Inc.

totopphone